Demographics and baseline disease characteristics
| Total no. of patients . | N = 225 . |
|---|---|
| Age, median (IQR), y | 59 (8) |
| Male | 127 (56.4) |
| Random assignment | |
| D-VTd + daratumumab | 59 (26.2) |
| VTd + daratumumab | 53 (23.5) |
| D-VTd + observation | 56 (24.9) |
| VTd + observation | 57 (25.3) |
| R-ISS stage | |
| I | 51 (23.1) |
| II | 151 (68.3) |
| III | 19 (8.6) |
| Not available | 4 (1.8) |
| Cytogenetic high-risk profile | 38 (16.9) |
| Negative baseline PET status | 50 (22.2) |
| Presence of FLs | 155 (68.9) |
| Presence of PMD | 35 (15.6) |
| Presence of EMD | 18 (8.0) |
| Diffuse BMI | 105 (46.7) |
| Total no. of patients . | N = 225 . |
|---|---|
| Age, median (IQR), y | 59 (8) |
| Male | 127 (56.4) |
| Random assignment | |
| D-VTd + daratumumab | 59 (26.2) |
| VTd + daratumumab | 53 (23.5) |
| D-VTd + observation | 56 (24.9) |
| VTd + observation | 57 (25.3) |
| R-ISS stage | |
| I | 51 (23.1) |
| II | 151 (68.3) |
| III | 19 (8.6) |
| Not available | 4 (1.8) |
| Cytogenetic high-risk profile | 38 (16.9) |
| Negative baseline PET status | 50 (22.2) |
| Presence of FLs | 155 (68.9) |
| Presence of PMD | 35 (15.6) |
| Presence of EMD | 18 (8.0) |
| Diffuse BMI | 105 (46.7) |
Data are presented as number (%) unless otherwise indicated.
BMI, bone marrow involvement; IQR, interquartile range.